Health Strategies Group

Name

Health Strategies Group

Website

https://healthstrategies.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

51–100 employees

Short description

Health Strategies Group, founded in 1992 and based in Lambertville, NJ, provides research-based sales and marketing intelligence to pharmaceutical and biotechnology companies. The firm is founder-led (Dee Prince, President) and operates with 51-100 employees.

Ownership category

akta.pro rank

Product category

Pharmaceutical Market Research

NAICS

Marketing Consulting Services (541613), Marketing Research and Public Opinion Polling (541910)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Pricing & Contracting Strategy (HLAIAKAA)

akta.pro secondary industry

Post-Approval Clinical Development (Phase IV & Lifecycle Management) (HLAIALAJ)

Keywords

• Pharmaceutical market intelligence
• Biotech sales research
• Pharma marketing research
• Life sciences consulting
• Biotech commercial insights

Headquarters

HQ city

Lambertville

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Core offering

Health Strategies Group provides research-based sales and marketing intelligence to the pharmaceutical and biotech industry. The firm delivers data-driven insights and consulting support that help life sciences commercial teams make strategic decisions on sales, marketing, pricing, and access. Engagements appear to be customized research projects for individual pharma and biotech clients.

Product overview

NAVLIN Insights is part of the NAVLIN Price & Access ecosystem by EVERSANA, which includes multiple integrated products: NAVLIN Price & Access Data, NAVLIN Price & Access Software, NAVLIN Insights, NAVLIN Daily, NAVLIN Revenue Management, and NAVLIN Contracts & Tender Management. NAVLIN Insights serves as the digital platform and policy tracker component, providing senior pharma leaders with real-time market access intelligence and portfolio performance visibility.

Differentiator

Problem solved

Functional benefit

Products and services

• Sales and Marketing Intelligence Research Research-based sales and marketing intelligence services for pharmaceutical and biotech companies. The offering delivers customized, data-driven insights to support commercial strategy and decision-making for life sciences clients.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights1 record

Broad incumbents

• EVERSANA: Owner of the NAVLIN Price & Access ecosystem under which NAVLIN Insights operates. EVERSANA is the closest ecosystem parent/commercial channel for HSG, distributing its market access intelligence alongside broader pharma commercialization services.
• Veeva Systems: Provides commercial software (CRM, data, and market access tools) to life sciences. Competes in adjacent layers of the pharma market access technology stack and is a de facto platform standard for many shared customers.
• IQVIA: Global leader in pharma data, analytics, and market access intelligence. IQVIA competes across pricing, HTA, and commercial benchmarking, with substantially larger datasets and consulting bench than HSG/NAVLIN Insights.

Direct peers

• ZS Associates: Management consulting firm with a deep pharma market access and pricing practice. ZS serves overlapping pharma customers on access strategy, pricing analytics, and launch excellence, often competing head-to-head on advisory engagements.
• Avalere Health: Healthcare policy and market access advisory firm. Avalere works with pharma clients on pricing, HTA, and reimbursement strategy — directly mirroring the market access intelligence and policy tracking value proposition of NAVLIN Insights.
• Trinity Life Sciences: Pharma strategy consulting firm with dedicated market access and pricing analytics offerings. Frequently partners with or competes against HSG-type intelligence providers on commercial strategy and brand benchmarking work.
• Definitive Healthcare: Healthcare commercial intelligence platform offering data on providers, payers, and life sciences markets. Overlaps with NAVLIN Insights in giving pharma and biotech commercial teams data-driven visibility for strategic decisions.
• Charles River Associates (CRA) - Life Sciences: Consulting practice with a strong life sciences focus, providing market access, pricing, and commercialization advisory. CRA's Life Sciences practice is a frequent peer on access and pricing engagements with pharma manufacturers.
• Informa Pharma Intelligence: Provides pharma and biotech market intelligence including pipeline, pricing, and access data. Overlaps with NAVLIN Insights in giving pharma commercial leaders intelligence to support portfolio and pricing decisions.

Others

• Health Technology Assessment (HTA) agencies (e.g., NICE, ICER): Public and quasi-public bodies that produce HTA and reimbursement analyses. While not commercial competitors, their outputs are core data inputs into HSG's NAVLIN Insights benchmarks and thus ecosystem participants in the same market access intelligence flow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/health-strategies-group
• Xx.com/hsgnews

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Health Strategies Group